Re: AGM agendas - Meetings Oct 31
in response to
by
posted on
Oct 10, 2019 12:36PM
"you don't think the ASN title from RVX that comes out tomorrow (assuming RVX gets in) will give some of the game away?"
No, I don't think that the ASN late breaker title (assuming RVX gets in) will necessarily tell us too much. For example, the title for the December CTAD BETonMACE cognition sub-study results is "Epigenetics, the BET-system, Alzheimer’s Disease and Vascular Cognitive Impairment; The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease." That title gives no indication of success or failure. Same thing could happen for potential ASN late breaker title for CKD sub-study. It could be a no give away neutral title. BUT......if Resverlogix chooses to, they could news release the top-line sub-study results prior to conference presentation to give an indication of success or failure. Tick tock.
BDAZ